Author:
Colaianna Marilena,Ilmjärv Sten,Peterson Hedi,Kern Ilse,Julien Stephanie,Baquié Mathurin,Pallocca Giorgia,Bosgra Sieto,Sachinidis Agapios,Hengstler Jan G.,Leist Marcel,Krause Karl-Heinz
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference141 articles.
1. Abrams PJ, Emerson CR (2009) Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy 29(2):167–181. doi: 10.1592/phco.29.2.167
2. Australian Therapeutic Goods Administration (2013) Australian Public Assessment Report for Teriflunomide.PM-2011-02772-3; http://www.tga.gov.au/pdf/auspar/auspar-teriflunomide-130521.pdf
3. Australian Therapeutic Goods Administration T (2014) Australian Public Assessment Report for Abiraterone Acetate. PM-2012-02706-3-4; https://www.tga.gov.au/word/auspar/ausparabiraterone-acetate-140122.docx
4. Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4(3):337–344. doi: 10.3233/JPD-140364
5. Baker H, Lindsey J, Weisbroth S (1979) The laboratory rat: biology and diseases, vol 1. Academic Press, London
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献